Biogen Enters $2 Billion Deal to Co-Develop Parkinson's Candidate in US and China

Biogen announced a $2 billion blockbuster deal to partner Denali Therapeutics' potential Parkinson's Disease therapy. In exchange for its $1 billion in upfront payments and $1 billion in milestones, Biogen will have rights to partner commercialization of Denali's small molecule LRRK2 inhibitors in the US and China, plus exclusive rights in the rest of the world. The agreement underscores that Denali, a South San Francisco company, considers China's market a significant factor in global marketing plans of its Parkinson's candidate. More details.... Stock Symbols: (NSDQ: BIIB) (NSDQ: DNLI) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.